Home > Insider Trading > Filing (0001193805-20-001473)

Filing Details

Accession Number:: 0001193805-20-001473
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-11-25 19:51:58
Reporting Period:: 2020-11-23

Accepted Time:: 2020-11-25 19:51:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599298	Summit Therapeutics Inc.	SMMT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1824493	Jonathan David Powell	One Broadway 14Th Floor Cambridge MA 02142	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-11-23	6,987	$1.92	6,987	No	4	M	Direct
Common Stock	Disposition	2020-11-23	6,987	$4.40	0	No	4	S	Direct
Common Stock	Acquisiton	2020-11-24	11,374	$1.92	11,374	No	4	M	Direct
Common Stock	Disposition	2020-11-24	11,374	$4.21	0	No	4	S	Direct
Common Stock	Acquisiton	2020-11-25	12,070	$1.92	12,070	No	4	M	Direct
Common Stock	Disposition	2020-11-25	12,070	$4.32	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-11-23	6,987	$1.92	6,987	$1.92
Common Stock	Stock Option (right to buy)	Disposition	2020-11-24	11,374	$1.92	11,374	$1.92
Common Stock	Stock Option (right to buy)	Disposition	2020-11-25	12,070	$1.92	12,070	$1.92

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
457,699	2028-10-19	No	4	X	Direct
446,325	2028-10-19	No	4	X	Direct
434,255	2028-10-19	No	4	X	Direct

Footnotes

Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.
The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.41 to $4.40. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.24 to $4.20. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.21. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.